Abstract
SUMMARY Aim: The objective of this study was to perform an indirect comparison between lenalidomide (LEN) and bortezomib (BORT). Methods: LEN and BORT are both effective for the treatment of patients with refractory multiple myeloma, but there are no head-to-head clinical trial data available. Therefore, an indirect statistical comparison between LEN and BORT was performed using the method of Bucher et al. Results: Three published randomized trials with LEN (n = 2) and BORT (n = 1) in the refractory setting were identified. Patients treated with LEN were significantly more likely to achieve a disease response (odds ratio: 1.92; 95% CI: 1.15–3.20) and to have a prolongation in time to progression (hazard ratio: 0.64; 95% CI: 0.44–0.91). Conclusion: Keeping in mind the caveats associated with cross-trial comparisons, the indirect statistical evaluation suggested the potential for increased activity of LEN over BORT in multiple myeloma patients with refractory disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
